Zeprumetostat is named as an intervention in 14 current clinical trials in our China and USA registers. 9 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (4). The most-studied condition is Lymphoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
NCT07175220 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
PDL1/TGFฮฒ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
NCT07294664 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, SHR1701
|
Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | China |
|
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470 · ClinicalTrials.gov ↗ · Follicular Lymphoma
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
NCT07717242 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Bladder Cancer
|
Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | China |
|
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 1/2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
NCT07502768 · Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma
|
Phase 1/2 | Recruiting | Rong Tao | China |
|
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803 · ClinicalTrials.gov ↗ · Lymphoma, Lymphoma, Non Hodgkin
|
Phase 1 | Recruiting | Treeline Biosciences, Inc. | USA |
|
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06679673 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic
|
Phase 2 | Not yet open | Fudan University | China |
|
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
NCT07347288 · ClinicalTrials.gov ↗ · PTCL
|
Phase 2 | Not yet open | The First Affiliated Hospital with Nanjing Medical University | China |
|
New Genotype-guided Treatment in Newly Diagnosed PTCL
NCT07706959 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma (PTCL)
|
Phase 1/2 | Not yet open | Ruijin Hospital | China |
|
Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL
NCT07724782 · ClinicalTrials.gov ↗ · PTCL-NOS
|
Phase 1/2 | Not yet open | Tianjin Medical University Cancer Institute and Hospital | China |
|
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
NCT06733441 · ClinicalTrials.gov ↗ · Lymphoma
|
Phase 1 | Active, closed | Treeline Biosciences, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Lymphoma | 2 |
| Advanced Gastric Cancer | 2 |
| Prostate Cancer | 2 |
| Lymphoma, Non Hodgkin | 1 |
| Extranodal NK/T-cell Lymphoma | 1 |
| NK/T-cell Lymphoma | 1 |
| Relapsed or Refractory NK/T-Cell Lymphoma | 1 |
| Follicular Lymphoma | 1 |
| Bladder Urothelial Carcinoma | 1 |
| Bladder Cancer | 1 |
| Peripheral T-cell Lymphoma (PTCL) | 1 |
| PTCL-NOS | 1 |
| PTCL | 1 |
| Metastatic Gastric Cancer | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| SHR1701 | 1 |
| Colorectal Cancer Metastatic | 1 |
| Locally Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 4 |
| Treeline Biosciences, Inc. | 2 |
| Rong Tao | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Ruijin Hospital | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Fudan University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 12 | 8 |
| Clinical trials in USA | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
14 current trials in our China and USA registers name Zeprumetostat (also registered as TLN-254) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 9 of the 14 trials are recruiting: 8 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (4), Treeline Biosciences, Inc (2), Rong Tao (1) and Institute of Hematology & Blood Diseases Hospital, China (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zeprumetostat works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Zeprumetostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zeprumetostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.